Yohann Loriot

3 ta ish

University of Paris-Sud

1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

   Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa +45

   Maqola20175 iqtibos

   ABIABI:AkademIndex/2026.other.339917

2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

   Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles +28

   MaqolaOAOchiq kirish20163 iqtibos

   ABIABI:AkademIndex/2026.other.097028

3. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

   Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles +39

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.121352